# NCT03635567 (NCT03635567)

> Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03635567
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Cervical Cancer
- Interventions: Pembrolizumab; Paclitaxel; Cisplatin; Carboplatin; Bevacizumab; Placebo to pembrolizumab
- Enrollment: 617
- Primary outcome: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1
- Primary outcome: PFS Per RECIST 1.1 as Assessed by Investigator in All Participants
- Primary outcome: PFS Per RECIST 1.1 as Assessed by Investigator in Participants With PD-L1 CPS ≥10
- Primary outcome: Overall Survival (OS) in Participants With PD-L1 CPS ≥1
- Primary outcome: OS in All Participants
- Primary outcome: OS in Participants With PD-L1 CPS ≥10

## Commentary we found

- YouTube: 23
- X threads: 19
- Podcasts: 17
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03635567

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03635567", "email": "<work email>"}; the inbox owner confirms by the emailed link.